Tamas Hickish

Tamas Hickish

  • thickish at bournemouth dot ac dot uk
Back to top

Journal Articles

  • Emile, J.F. et al., 2017. Prospective validation of a lymphocyte infiltration prognostic test in stage III colon cancer patients treated with adjuvant FOLFOX. European Journal of Cancer, 82, 16-24.
  • Thomas, J.S.J., Hickish, T. et al., 2017. Central pathology review with two-stage quality assurance for pathological response after neoadjuvant chemotherapy in the ARTemis Trial. Modern Pathology, 30 (8), 1069-1077.
  • Earl, H.M., Hickish, T. et al., 2017. Addition of gemcitabine to paclitaxel, epirubicin, and cyclophosphamide adjuvant chemotherapy for women with early-stage breast cancer (tAnGo): final 10-year follow-up of an open-label, randomised, phase 3 trial. LANCET ONCOLOGY, 18 (6), 755-769.
  • Middleton, G., Hickish, T. et al., 2017. Vandetanib plus gemcitabine versus placebo plus gemcitabine in locally advanced or metastatic pancreatic carcinoma (ViP): a prospective, randomised, double-blind, multicentre phase 2 trial. LANCET ONCOLOGY, 18 (4), 486-499.
  • Hickish, T., Hickish, T. et al., 2017. MABp1 as a novel antibody treatment for advanced colorectal cancer: a randomised, double-blind, placebo-controlled, phase 3 study. LANCET ONCOLOGY, 18 (2), 192-201.
  • Pugh, S.A., Hickish, T. et al., 2016. Patterns of progression, treatment of progressive disease and post-progression survival in the New EPOC study. British Journal of Cancer, 115 (4), 420-424.
  • Pritchard, C., Hickish, T., Rosenorn-Lanng, E. and Wallace, M., 2016. Comparing UK and 20 Western countries' efficiency in reducing adult (55-74) cancer and total mortality rates 1989-2010: Cause for cautious celebration? A population-based study. JRSM open, 7 (6), 2054270416635036.
  • Ali, H.R., Hickish, T. et al., 2016. Computational pathology of pre-treatment biopsies identifies lymphocyte density as a predictor of response to neoadjuvant chemotherapy in breast cancer. BREAST CANCER RESEARCH, 18.
  • Andre, T., Hickish, T. et al., 2015. Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study. JOURNAL OF CLINICAL ONCOLOGY, 33 (35), 4176-+.
  • Sclafani, F., Hickish, T. et al., 2015. Short-and Long-Term Quality of Life and Bowel Function in Patients With MRI-Defined, High-Risk, Locally Advanced Rectal Cancer Treated With an Intensified Neoadjuvant Strategy in the Randomized Phase 2 EXPERT-C Trial. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 93 (2), 303-312.
  • Primrose, J.N., Hickish, T. et al., 2015. Cetuximab is contraindicated in the perioperative treatment of colorectal liver metastases. Journal of Clinical Oncology, 33 (21), 2405-2406.
  • Earl, H.M., Hickish, T. et al., 2015. Efficacy of neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin, and cyclophosphamide, for women with HER2-negative early breast cancer (ARTemis): an open-label, randomised, phase 3 trial. The Lancet. Oncology, 16 (6), 656-666.
  • Abbey, G., Thompson, S.B.N. and Hickish, T., 2015. A meta-analysis of prevalence rates and moderating factors for cancer-related post-traumatic stress disorder. Psycho-Oncology, 24 (4), 371-381.
  • Sclafani, F., Hickish, T. et al., 2015. Short- and long-term quality of life and bowel function in patients with MRI-defined, high-risk, locally advanced rectal cancer treated with an intensified neoadjuvant strategy in the randomized phase 2 EXPERT-C trial. International Journal of Radiation Oncology Biology Physics, 93 (2), 303-312.
  • Purandare, L. and Hickish, T., 2015. Acceptability and safety of telemedicine to assess patients before chemotherapy. Cancer Nursing Practice, 14 (6), 20-24.
  • Gillis, C., McLaughlin, P., Osselton, D., Hickish, T. and Mactier, H., 2015. Genetic and epigenetic variations and gene methylation in infants exposed to methadone in-utero. British Association of Perinatal Medicine; Arch Dis Child.
  • Mishu, M.C., Dubey, V.N., Hickish, T. and Cole, J., 2014. A Review on Pressure Ulcer: Aetiology, Cost, Detection and Prevention Systems. International Journal of Engineering Sciences & Research Technology, 3 (9), 419-428.
  • Middleton, G., Hickish, T. et al., 2014. Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial. Lancet Oncol, 15 (8), 829-840.
  • Masters, B., Hickish, T. and Cidon, E.U., 2014. A midline for oxaliplatin infusion: the myth of safety devices. BMJ Case Rep, 2014.
  • Mishu, M.C., Dubey, V.N., Hickish, T. and Cole, J., 2014. Mathematical Modelling of Different Types of Body Support Surface for Pressure Ulcer Prevention. International Journal of Medical, Pharmaceutical Science and Engineering, 8 (5), 209-214.
  • Yao, C., Nash, G.F. and Hickish, T., 2014. Management of colorectal cancer and diabetes. J R Soc Med, 107 (3), 103-109.
  • Molife, L.R., Hickish, T. et al., 2014. Randomized Phase II trial of nintedanib, afatinib and sequential combination in castration-resistant prostate cancer. Future Oncol, 10 (2), 219-231.
  • Earl, H.M., Hickish, T. et al., 2014. Effects of the addition of gemcitabine, and paclitaxel-first sequencing, in neoadjuvant sequential epirubicin, cyclophosphamide, and paclitaxel for women with high-risk early breast cancer (Neo-tAnGo): an open-label, 2×2 factorial randomised phase 3 trial. Lancet Oncol, 15 (2), 201-212.
  • Pan, J.J., Chang, J., Yang, X., Zhang, J.J., Qureshi, T., Howell, R., Hickish, T. and Liang, H., 2014. Virtual reality training and assessment in laparoscopic rectum surgery. International Journal of Medical Robotics and Computer Assisted Surgery.
  • Primrose, J., Hickish, T. et al., 2014. Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis: The New EPOC randomised controlled trial. The Lancet Oncology, 15 (6), 601-611.
  • Wasan, H. et al., 2014. Intermittent chemotherapy plus either intermittent or continuous cetuximab for first-line treatment of patients with KRAS wild-type advanced colorectal cancer (COIN-B): a randomised phase 2 trial. Lancet Oncology, 15 (6), 631-639.
  • Hickish, T., Hickish, T. et al., 2014. A randomised, open-label phase II trial of afatinib versus cetuximab in patients with metastatic colorectal cancer. European Journal of Cancer, 50, 3136-3144.
  • Awada, A., Hickish, T. et al., 2013. The ENCHANT-1 trial (NCT01677455): An open label multicenter phase 2 proof of concept study evaluating first line ganetespib monotherapy in women with metastatic HER2 positive or triple negative obreast cancer (TNBC). CANCER RESEARCH, 73.
  • Schneeweiss, A., Hickish, T. et al., 2013. Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA). Ann Oncol, 24 (9), 2278-2284.
  • Agbamu, D.A., Hickish, T.F.G. et al., 2012. Feasibility of preoperative chemotherapy for locally advanced, operable colon cancer: The pilot phase of a randomised controlled trial. The Lancet Oncology, 13 (11), 1152-1160.
  • Hickish, T. and Farmery, A.D., 2012. Acid-base physiology: New concepts. Anaesthesia and Intensive Care Medicine, 13 (11), 567-572.
  • Nash, G.F., Turner, K.J., Hickish, T., Smith, J., Chand, M. and Moran, B.J., 2012. Interactions in the aetiology, presentation and management of synchronous and metachronous adenocarcinoma of the prostate and rectum. Ann R Coll Surg Engl, 94 (7), 456-462.
  • Tournigand, C., Hickish, T. et al., 2012. Adjuvant therapy with fluorouracil and oxaliplatin in stage II and elderly patients (between ages 70 and 75 years) with colon cancer: subgroup analyses of the Multicenter International Study of Oxaliplatin, Fluorouracil, and Leucovorin in the Adjuvant Treatment of Colon Cancer trial. J Clin Oncol, 30 (27), 3353-3360.
  • Dunlop, M.G. et al., 2012. Common variation near CDKN1A, POLD3 and SHROOM2 influences colorectal cancer risk. Nature Genetics, 44 (7), 770-776.
  • Lin, N.U., Hickish, T. et al., 2012. A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab. Breast Cancer Research and Treatment, 133 (3), 1057-1065.
  • Moyers-Ruiz, L., Hickish, T. and Thompson, S.B.N., 2012. Prospective and working memory decline as a result of impaired sleep and/or impaired blood glucose in breast cancer patients during chemotherapy treatment. Journal of Clinical Oncology, 30 ((Suppl), abstr), TPS9148.
  • Moyers-Ruiz, L., Thompson, S. and Hickish, T., 2012. Investigation Of Prospective And Working Memory Decline And The Impact Of Impaired Sleep And/Or Glucose Metabolism In Recently Diagnosed Breast Cancer Patients Undergoing Chemotherapy: A Longitudinal Study. PSYCHO-ONCOLOGY, 21, 6.
  • Schroeder, J., Dubey, V., Hickish, T. and Cole, J., 2012. Case Study on Repeatability of a Threshold-Based Calibration Method for Electrocutaneous Feedback Systems. Journal of Medical Devices, 6 (1).
  • Schroeder, J., Dubey, V., Hickish, T. and Cole, J., 2012. Wearable Electrocutaneous Feedback System: A Smart Device to Compensate for Sensation Loss. Journal of Medical Devices, 6 (1).
  • Moyers-Ruiz, L., Hickish, T. and Thompson, S.B.N., 2012. Prospective and working memory decline as a result of impaired sleep and/or impaired blood glucose in breast cancer patients during chemotherapy treatment. Journal of Clinical Oncology, 30 (Suppl), TPS9148.
  • Thompson, S., Eccleston, L. and Hickish, T.F., 2011. Post-traumatic stress disorder on cancer survivors: recognising and acknowledging the symptoms. WMC Oncology, 2, 1-16.
  • Adams, R.A., Hickish, T. et al., 2011. Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. Lancet Oncol, 12 (7), 642-653.
  • Seymour, M.T., Hickish, T. et al., 2011. Addition of panitumumab to irinotecan: Results of PICCOLO, a randomized controlled trial in advanced colorectal cancer (aCRC). J Clin Oncol, 29 (15_suppl), 3523.
  • Pritchard, C. and Hickish, T.F., 2011. Cancer survival in Australia, Canada, Denmark, Norway, Sweden and the UK. Lancet, 377, 1149.
  • Pritchard, C. and Hickish, T.F., 2011. Comparing cancer mortality and GDP health expenditure in England and Wales with other major developed countries from 1979 to 2006. British Journal of Cancer.
  • Toumigand, C., Hickish, T. et al., 2010. FOLFOX4 as adjuvant therapy in elderly patients (pts) with colon cancer (CC): Subgroup analysis of the MOSAIC trial. JOURNAL OF CLINICAL ONCOLOGY, 28 (15).
  • Teixeira, L., Hickish, T. et al., 2010. Efficacy of FOLFOX4 as adjuvant therapy in stage II colon cancer (CC): A new analysis of the MOSAIC trial according to risk factors. JOURNAL OF CLINICAL ONCOLOGY, 28 (15).
  • Pan, J., Chang, J., Yang, X., Zhang, J., Qureshi, T., Howell, R.D. and Hickish, T.F., 2010. Graphic and haptic simulation system for virtual laparoscopic rectum surgery. International Journal of Medical Robotics and Computer Assisted Surgery, 7.
  • Cunningham, D. and Hickish, T.F., 2010. A multicentre phase II study of capecitabine, oxaliplatin plus bevacizumab as peri-operative treatment for patients with poor risk colorectal liver-only metastases unsuitable for upfront resection. Journal of Clinical Oncology.
  • Sirohi, B., Hickish, T.F. et al., 2010. A randomized comparative trial of infusional ECisF versus conventional FEC as adjuvant chemotherapy in early breast cancer: the TRAFIC trial. Annals of Oncology, 21, 1623-1629.
  • Houston, S., Grieve, R.J., Hickish, T.F., Percival, F. and Hamilton, E., 2010. Renal function changes and NHS resource use in breast cancer patients with metastatic bone disease treated with IV zoledronic acid or oral ibandronic acid: a four-centre non-interventional study. Journal of Medical Economics, 13, 162-167.
  • Earl, H.M., Hickish, T. et al., 2009. Neo-tAnGo: A neoadjuvant randomized phase III trial of epirubicin/cyclophosphamide and paclitaxel ± gemcitabine in the treatment of women with high-risk early breast cancer (EBC): First report of the primary endpoint, pathological complete response (pCR). J Clin Oncol, 27 (15_suppl), 522.
  • Hickish, T., Wheatley, D., Lin, N., Carey, L., Houston, S., Mendelson, D., Solca, F., Uttenreuther-Fischer, M., Jones, H. and Winer, E., 2009. Use of BIBW 2992, a novel irreversible EGFR/HER2 tyrosine kinase inhibitor (TKI), to treat patients with HER2-positive metastatic breast cancer after failure of treatment with trastuzumab. J Clin Oncol, 27 (15_suppl), 1023.
  • Chau, I., Norman, A.R., Cunningham, D., Oates, J., Hawkins, R., Iveson, T., Nicolson, M., Harper, P., Seymour, M. and Hickish, T., 2009. The impact of primary tumour origins in patients with advanced oesophageal, oesophago-gastric junction and gastric adenocarcinoma--individual patient data from 1775 patients in four randomised controlled trials. Ann Oncol, 20 (5), 885-891.
  • Hickish, T.F., Astras, G., Thomas, P., Penfold, S., Purandare, L. and Kerr, D., 2009. Glucose intolerance during adjuvant chemotherapy for breast cancer. Correspondence. Journal of the National Cancer Institute, 101, 537.
  • Boni, C., Andre, T., Banzi, M.C., Hickish, T.F., Tabernero, J., Clingan, P., Chibaudel, B. and De Gramont, A., 2009. Similarities and differences between the adjuvant oxaliplatin-based trials, MOSAIC and NSABP C-07. Current Colorectal Cancer Reports, 5, 166-170.
  • Andre, T., Hickish, T.F. et al., 2009. Improved overall survival with oxaliplatin, fluorouracil and leucovorin as adjuvant treatment in stage II / III colon cancer: update from a randomised controlled trial. Journal of Clinical Oncology, 27, 3109-3116.
  • Pritchard, C. and Hickish, T.F., 2008. Changes in Cancer Incidence and Mortality in England & Wales and a comparison of cancer deaths in the Major Developed Countries by Age and Sex 1979-2002 in context of GDP Expenditure on Health. ecancermedicalscience, 2, 1-18.
  • Hemandas, A.K., Robson, N.K., Hickish, T.F. and Talbot, R.W., 2008. Colorectal tubulovillous adenomas identified on fluoro-2-deoxy-d-glucose positron emission tomography/computed tomography scans. Colorectal Disease, 10, 386-389.
  • Hickish, T., Chau, I., Massey, A., Higgins, L., Osborne, R., Botwood, N., Swaisland, A. and Cunningham, D.C., 2006. Gefitinib and irinotecan in patients with fluoropyrimidine-refractory irinotecan-naïve advanced colorectal cancer (CRC): dose-finding, pharmacokinetics, safety and efficacy. J Clin Oncol, 24 (18_suppl), 13520.
  • Cassidy, J., Bjarnason, G.A., Hickish, T., Topham, C., Provencio, M., Bodoky, G., Landherr, L., Koralewski, P., Lopez-Vivanco, G. and Said, G., 2006. Randomized double blind (DB) placebo (Plcb) controlled phase III study assessing the efficacy of xaliproden (X) in reducing the cumulative peripheral sensory neuropathy (PSN) induced by the oxaliplatin (Ox) and 5-FU/LV combination (FOLFOX4) in first-line treatment of patients (pts) with metastatic colorectal cancer (MCRC). J Clin Oncol, 24 (18_suppl), 3507.
  • Chau, I., Hickish, T.F. et al., 2006. Gastrazole (JB95008), a novel CCK2/gastrin receptor antagonist, in the treatment of advanced pancreatic cancer: results from two randomised controlled trials. British Journal of Cancer, 94, 1107-1115.
  • Chau, I., Cunningham, D., Hickish, T.F., Massey, A., Higgins, L., Osborne, R.J., Botwood, N. and Swaisland, A., 2006. Gefitinib and irinotecan in patients with fluoropyrimidine-refractory, irinotecan-naive advanced colorectal cancer: a phase I-II study. Annals of Oncology, 18, 730-737.
  • Hickish, T.F., 2006. Administration of cetuximab in managing colorectal cancer. Cancer Nursing Practice, 5, 28-29.
  • Trumper, M., Ross, P.J., Cunningham, D., Norman, A.R., Hawkins, R., Seymour, M.T.J., Harper, P., Iveson, T.J., Nicolson, M.C. and Hickish, T.F., 2006. Efficacy and tolerability of chemotherapy in elderly patients with advanced oesophago-gastric cancer: A pooled analysis of three clinical trials. European Journal of Cancer, 42, 827-834.
  • Chau, I., Hickish, T.F. et al., 2005. Longitudinal quality of life and quality adjusted survival in a randomised controlled trial comparing six months of bolus fluorouracil/leucovorin twelve weeks of protracted venous infusion fluorouracil as adjuvant chemotherapy for colorectal cancer. European Journal of Cancer, 41, 1551-1559.
  • Chua, S., Hickish, T.F. et al., 2005. Neoadjuvant vinorelbine/epirubicin (VE) versus standard adriamycin/cyclophosphamide (AC) in operable breast cancer: analysis of response and tolerability in a randomised phase III trial (TOPIC 2). Annals of Oncology, 16, 1435-1441.
  • Sumpter, K., Hickish, T.F. et al., 2005. Report of two protocol planned interim analyses in a randomised multicentre phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric cancer receiving ECF. British Journal of Cancer, 92, 1976-1983.
  • Chau, I., Hickish, T. et al., 2005. A randomised comparison between 6 months of bolus fluorouracil/leucovorin and 12 weeks of protracted venous infusion fluorouracil as adjuvant treatment in colorectal cancer. Ann Oncol, 16 (4), 549-557.
  • Mandalà, M., Ferretti, G., Barni, S., De Gramont, A., André, T. and Hickish, T., 2004. Oxaliplatin in colon cancer [3] (multiple letters). New England Journal of Medicine, 351 (16), 1691-1692.
  • Norman, A.R., Chau, I., Iveson, T., Hill, M., Hickish, T., Lofts, F., Jodrell, D., Shellito, P., Oates, J. and Cunningham, D., 2004. Longitudinal quality of life (QoL) and quality adjusted survival (QAS) in a randomised controlled trial (RCT) comparing bolus (24 weeks) vs. protracted venous infusion (PVI 12 weeks) 5-FU as adjuvant chemotherapy for colorectal cancer (CRC). J Clin Oncol, 22 (14_suppl), 3625.
  • Hickish, T., Boni, C., Navarro, M., Tabernero, J., Topham, C., Bonetti, A., Clingan, P., Figer, A., Andre, T. and De Gramont, A., 2004. FOLFOX4 as adjuvant treatment for stage II colon cancer (CC): Subpopulation data from the MOSAIC trial. J Clin Oncol, 22 (14_suppl), 3619.
  • Starling, N., Chau, I., Norman, A.R., Tait, D., Iveson, T., Hill, M., Hickish, T., Lofts, F., Jodrell, D. and Cunningham, D., 2004. A randomised comparison between six months of bolus fluorouracil (5-FU)/leucovorin (LV) and twelve weeks of protracted venous infusion (PVI) 5-FU as adjuvant treatment in colorectal cancer: An update with 5 years' follow-up. J Clin Oncol, 22 (14_suppl), 3523.
  • Trumper, M.J., Norman, A.R., Ross, P.J., Cunningham, D., Hawkins, R., Seymour, M., Harper, P., Iveson, T., Nicholson, M. and Hickish, T., 2004. Patients aged 70 or older (≥ 70) with advanced oesophagogastric cancer (OGC) experience similar benefits from palliative chemotherapy compared to younger patients. J Clin Oncol, 22 (14_suppl), 4018.
  • Andre, T., Hickish, T.F. et al., 2004. Oxaliplatin, Fluorouracil, and Leucovorin as Adjuvant Treatment for Colon Cancer. New England Journal of Medicine, 350, 2343-2351.
  • O'Brien, M.E.R., Hickish, T. et al., 2004. SRL 172 (killed Mycobacterium vaccae) in addition to standard chemotherapy improves quality of life without affecting survival, in patients with advanced non-small-cell lung cancer: Phase III results. Annals of Oncology, 15 (6), 906-914.
  • Papazisis, K.T., Hickish, T. et al., 2004. Safety and efficacy of the combination of trastuzumab with docetaxel for HER2-positive women with advanced breast cancer. A review of the existing clinical trials and results of the expanded access programme in the UK. International Journal of Clinical Practice, 58 (6), 581-586.
  • Smith, I.E., Hickish, T.F. et al., 2004. A novel continuous infusional 5-fluorouracil-based chemotherapy regimen compared with conventional chemotherapy in the neo-adjuvant treatment of early breast cancer: 5 year results of the TOPIC trial. Annals of Oncology, 15, 751-758.
  • Price, T.J., Hickish, T.F. et al., 2004. Phase III Study of Mitomycin-C with Protracted Venous Infusion or Circadian-Timed Infusion of 5-Fluorouracil in Advanced Colorectal Carcinoma. Clinical Colorectal Cancer, 3, 235-242.
  • de Gramont, A., Boni, C., Navarro, M., Tabernero, J., Hickish, T., Topham, C., Bonetti, A., Clingan, P., Marceau-Suissa, J. and Andre, T., 2004. Oxaliplatin/5FU/LV in stage II and III Colon Cancer: Updated results (as of January 04) for efficacy and neurotoxicity of the MOSAIC trial. ANNALS OF ONCOLOGY, 15, 73.
  • Ross, P.J., Trumper, M., Norman, A.R., Hawkins, R., Seymour, M., Harper, P.G., Iveson, T., Nicolson, M., Hickish, T. and Cunningham, D., 2004. An analysis of the outcome to palliative chemotherapy for oesophagogastric (OGC) cancer in patients aged 70 years and older (>= 70) with younger patients. ANNALS OF ONCOLOGY, 15, 230.
  • Hickish, T., Boni, C., Navarro, M., Tabernero, J., Bonetti, A., Clingan, P., Figer, A., Andre, T. and de Gramont, A., 2004. Stage II patients in the "MOSAIC" trial evaluating Oxaliplatin/5FU/LV as adjuvant treatment of colon cancer: a subpopulation analysis. ANNALS OF ONCOLOGY, 15, 76.
  • Saini, A., Hickish, T.F. et al., 2003. Twelve weeks of protracted venous infusion of fluorouracil (5-FU) is as effective as 6 months of bolus 5-FU and folinic acid as adjuvant treatment in colorectal cancer. British Journal Of Cancer, 88, 1859-1866.
  • Assersohn, L., Norman, A.R., Cunningham, D., Iveson, T.J., Seymour, M.T.J., Hickish, T.F., Massey, A., Prior, Y. and Hilla, M.E., 2003. A randomised study of protracted venous infusion of 5-fluorouracil (5-FU) with or without bolus mitomycin C (MMC) in patients with carcinoma of unknown primary. European Journal of Cancer, 39, 1121-1128.
  • Johnston, S.R.D., Hickish, T.F. et al., 2003. Phase II Study of the Efficacy and Tolerability of Two Dosing Regimens of the Farnesyl Transferase Inhibitor, R115777, in Advanced Breast Cancer. Journal of Clinical Oncology, 21, 2492-2499.
  • Maisey, N.R., Hickish, T.F. et al., 2002. Multicenter Randomized Phase III Trial Comparing Protracted Venous Infusion (PVI) Fluorouracil (5-FU) With PVI 5-FU Plus Mitomycin in Inoperable Pancreatic Cancer. Journal of Clinical Oncology, 20, 3130-3136.
  • Ross, P.J., Hickish, T.F. et al., 2002. Prospective Randomized Trial Comparing Mitomycin, Cisplatin, and Protracted Venous-Infusion Fluorouracil (PVI 5-FU) With Epirubicin, Cisplatin, and PVI 5-FU in Advanced Esophagogastric Cancer. Journal of Clinical Oncology, 20, 1996-2004.
  • Tebbutt, N.C., Hickish, T. et al., 2002. A muticentre, randomised phase III trial comparing protracted venous infusion (PVI) 5-fluorouracil (5-FU) with PVI 5-FU plus mitomycin C in patients with inoperable oesophago-gastric cancer. Annals of Oncology, 13 (10), 1568-1575.
  • Donnelly, J., Parham, D.M., Hickish, T.F., Chan, H.Y. and Skene, A.I., 2001. Axillary lymph node scarring and the association with tumour response following neoadjuvant chemoendocrine therapy for breast cancer. The Breast, 10, 61-66.
  • Smith, I.E., O Brien, M.E.R., Talbot, D.C., Nicolson, M.C., Mansi, J.L., Hickish, T.F., Norton, A. and Ashley, S., 2001. Duration of Chemotherapy in Advanced Non–Small-Cell Lung Cancer: A Randomized Trial of Three Versus Six Courses of Mitomycin, Vinblastine, and Cisplatin. Journal of Clinical Oncology, 19, 1336-1343.
  • Smith, I.E., A'Hern, R.P., Ebbs, S., Howell, A., Hickish, T., O'Brien, M., Robinson, A., Wilson, C. and Grp, T.O.P.I.C.T., 2000. Preoperative continuous infusional (epirubicin, cisplatin and infusional 5 FU) v. conventional AC chemotherapy for early breast cancer: As phase III randomised trial. BRITISH JOURNAL OF CANCER, 83, 2.
  • Smith, I.E., Johnston, S.R.D., O Brien, M.E.R., Hickish, T.F., de Boer, R.H., Norton, A., Cirkel, D.T. and Barton, C.M., 2000. Low-Dose Oral Fluorouracil With Eniluracil as First-Line Chemotherapy Against Advanced Breast Cancer: A Phase II Study. Journal of Clinical Oncology, 18, 2378-2384.
  • Iveson, T.J., Hickish, T., Schmitt, C. and Van Cutsem, E., 1999. Irinotecan in second-line treatment of metastatic colorectal cancer: improved survival and cost-effect compared with infusional 5-FU. Eur J Cancer, 35 (13), 1796-1804.
  • Ross, P., Hickish, T. et al., 1999. Results of a randomised trial comparing ECF with MCF in advanced oesophago-gastric cancer. EUROPEAN JOURNAL OF CANCER, 35, S137.
  • Price, T., Cunningham, D., Hickish, T., Tait, D., Norman, A., Ross, P.J., Middleton, G., Ford, H.E.R., Sumpter, K. and Hill, M., 1999. Dose intensification of 5 fluorouracil by chronomodulation in a phase III trial for advanced colorectal carcinoma. BRITISH JOURNAL OF CANCER, 80, 20.
  • Waters, J.S., Hickish, T. et al., 1999. Long-term survival after epirubicin, cisplatin and fluorouracil for gastric cancer: results of a randomized trial. Br J Cancer, 80 (1-2), 269-272.
  • Middleton, G.W., Smith, I.E., O'Brien, M.E.R., Norton, A., Hickish, T., Priest, K. and Spencer, L., 1998. Good symptom relief with palliative MVP mitomycin-C, vinblastine and cisplatin chemotherapy in malignant mesothelioma. Pneumologie, 52 (7), 432.
  • Makris, A., Powles, T.J., Ashley, S.E., Chang, J., Hickish, T., Tidy, V.A., Nash, A.G. and Ford, H.T., 1998. A reduction in the requirements for mastectomy in a randomized trial of neoadjuvant chemoendocrine therapy in primary breast cancer. Ann Oncol, 9 (11), 1179-1184.
  • Cunningham, D., Hickish, T.F. et al., 1998. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet, 352 (9138), 1413-1418.
  • Cunningham, D., Hickish, T. et al., 1998. A randomized trial of maintenance interferon following high-dose chemotherapy in multiple myeloma: long-term follow-up results. Br J Haematol, 102 (2), 495-502.
  • Hickish, T.F., Smith, I.E., O'Brien, M.E.R., Ashley, S. and Middleton, G., 1998. Clinical benefit from palliative chemotherapy in non-small-cell lung cancer extends to the elderly and those with poor prognostic factors. British Journal of Cancer, 78 (1), 28-33.
  • Middleton, G.W., Smith, I.E., O'Brien, M.E., Norton, A., Hickish, T., Priest, K., Spencer, L. and Ashley, S., 1998. Good symptom relief with palliative MVP (mitomycin-C, vinblastine and cisplatin) chemotherapy in malignant mesothelioma. Ann Oncol, 9 (3), 269-273.
  • Hickish, T.F., Smith, I.E., Nicolson, M.C., Ashley, S., Priest, K., Spencer, L., Norman, A., Middleton, G. and O'Brien, M.E.R., 1998. A pilot study of MVP (mitomycin-C, vinblastine and cisplatin) chemotherapy in small-cell lung cancer. British Journal of Cancer, 77 (11), 1966-1970.
  • Beale, P., Judson, I., Hanwell, J., Berry, C., Aherne, W., Hickish, T., Martin, P. and Walker, M., 1998. Metabolism, excretion and pharmacokinetics of a single dose of [14C]-raltitrexed in cancer patients. Cancer Chemother Pharmacol, 42 (1), 71-76.
  • Iveson, T., Eggleton, S.P.H., Hickish, T., Cunningham, D., Maughan, T. and Harper, P., 1998. Irinotecan (CPT-11) in 5-FU pretreated advanced colorectal cancer: Results in 174 expanded access patients. ANNALS OF ONCOLOGY, 9, 36-37.
  • Mattia, E., Chichiarelli, S., Hickish, T., Gaeta, A., Mancini, C., Cunningham, D. and van Renswoude, J., 1997. Inhibition of in vitro proliferation of Epstein Barr Virus infected B cells by an antisense oligodeoxynucleotide targeted against EBV latent membrane protein LMP1. Oncogene, 15 (4), 489-493.
  • Webb, A., Hickish, T. et al., 1997. Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol, 15 (1), 261-267.
  • Mainwaring, P.N., Nicolson, M.C., Hickish, T., Penson, R., Joel, S., Slevin, M. and Smith, I.E., 1997. Continuous infusional topotecan in advanced breast and non-small-cell lung cancer: no evidence of increased efficacy. Br J Cancer, 76 (12), 1636-1639.
  • Hickish, T.F., Smith, I.E., Ashley, S. and Middleton, G., 1996. Chemotherapy for elderly patients with lung cancer. Pneumologie, 50 (7), 503.
  • O'Brien, M.E., Milan, S., Cunningham, D., Jones, A.L., Nicolson, M., Selby, P., Hickish, T., Hill, M., Gore, M.E. and Viner, C., 1996. High-dose chemotherapy and autologous bone marrow transplant in relapsed Hodgkin's disease--a pragmatic prognostic index. Br J Cancer, 73 (10), 1272-1277.
  • Powles, R., Raje, N., Horton, C., Mehta, J., Singhal, S., Hickish, T., Viner, C., Milan, S., Treleaven, J. and Cunningham, D., 1996. Comparison of interferon tolerance after autologous bone marrow or peripheral blood stem cell transplants for myeloma patients who have responded to induction therapy. Leuk Lymphoma, 21 (5-6), 421-427.
  • Findlay, M., Young, H., Cunningham, D., Iveson, A., Cronin, B., Hickish, T., Pratt, B., Husband, J., Flower, M. and Ott, R., 1996. Noninvasive monitoring of tumor metabolism using fluorodeoxyglucose and positron emission tomography in colorectal cancer liver metastases: correlation with tumor response to fluorouracil. J Clin Oncol, 14 (3), 700-708.
  • Modjtahedi, H., Hickish, T. et al., 1996. Phase I trial and tumour localisation of the anti-EGFR monoclonal antibody ICR62 in head and neck or lung cancer. Br J Cancer, 73 (2), 228-235.
  • Powles, T.J., Hickish, T., Kanis, J.A., Tidy, A. and Ashley, S., 1996. Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women. J Clin Oncol, 14 (1), 78-84.
  • Nicolson, M., Webb, A., Cunningham, D., Norman, A., O'Brien, M., Hill, A. and Hickish, T., 1995. Cisplatin and protracted venous infusion 5-fluorouracil (CF)--good symptom relief with low toxicity in advanced pancreatic carcinoma. Ann Oncol, 6 (8), 801-804.
  • Powles, T.J. and Hickish, T., 1995. Tamoxifen therapy and carcinogenic risk. J Natl Cancer Inst, 87 (18), 1343-1345.
  • Hill, M., Norman, A., Cunningham, D., Findlay, M., Watson, M., Nicolson, V., Webb, A., Middleton, G., Ahmed, F. and Hickish, T., 1995. Impact of protracted venous infusion fluorouracil with or without interferon alfa-2b on tumor response, survival, and quality of life in advanced colorectal cancer. J Clin Oncol, 13 (9), 2317-2323.
  • Hickish, T.F., Smith, I.E., Ashley, S. and Middleton, G., 1995. Chemotherapy for elderly patients with lung cancer. The Lancet, 346 (8974), 580.
  • Powles, T.J. and Hickish, T., 1995. Breast cancer response to hormone replacement therapy withdrawal. Lancet, 345 (8962), 1442.
  • Eisen, T., Hickish, T., Smith, I.E., Sloane, J. and Eccles, S., 1995. Small-cell lung cancer. Report of a Meeting of POhysicians and Scientists at the Royal Marsden Hospital, Sutto, UK. The Lancet, 345 (8960), 1285-1289.
  • Hickish, T.F., Smith, I.E., Mlddleton, G. and Nicolson, M., 1995. Patient preference for extended palliative chemotherapy for non-small cell lung cancer. The Lancet, 345 (8953), 857-858.
  • Powles, T.J., Hickish, T.F. et al., 1995. Randomized trial of chemoendocrine therapy started before or after surgery for treatment of primary breast cancer. Journal of Clinical Oncology, 13 (3), 547-552.
  • Hill, M., Hickish, T. et al., 1995. Evaluation of the efficacy of the VEEP regimen in adult Hodgkin's disease with assessment of gonadal and cardiac toxicity. Journal of Clinical Oncology, 13 (2), 387-395.
  • Ellis, P.A., Norman, A., Hill, A., O'Brien, M.E.R., Nicolson, M., Hickish, T. and Cunningham, D., 1995. Epirubicin, cisplatin and infusional 5-fluorouracil (5-FU) (ECF) in hepatobiliary tumours. European Journal of Cancer, 31 (10), 1594-1598.
  • McMaster, T.J., Hickish, T., Min, T., Cunningham, D. and Miles, M.J., 1994. Application of scanning force microscopy to chromosome analysis. Cancer Genet Cytogenet, 76 (2), 93-95.
  • Findlay, M., Cunningham, D., Norman, A., Mansi, J., Nicolson, M., Hickish, T., Nicolson, V., Nash, A., Sacks, N. and Ford, H., 1994. A phase II study in advanced gastro-esophageal cancer using epirubicin and cisplatin in combination with continuous infusion 5-fluorouracil (ECF). Ann Oncol, 5 (7), 609-616.
  • Hickish, T.F. and Cunningham, D., 1994. Should induction chemotherapy be considered for all patients with gastric cancer? European Journal of Surgical Oncology, 20 (2), 185-186.
  • Hickish, T., Robertson, D., Clarke, P., Hill, M., di Stefano, F., Clarke, C. and Cunningham, D., 1994. Ultrastructural localization of BHRF1: an Epstein-Barr virus gene product which has homology with bcl-2. Cancer Res, 54 (10), 2808-2811.
  • Cunningham, D., Paz-Ares, L., Gore, M.E., Malpas, J., Hickish, T., Nicolson, M., Meldrum, M., Viner, C., Milan, S. and Selby, P.J., 1994. High-dose melphalan for multiple myeloma: long-term follow-up data. J Clin Oncol, 12 (4), 764-768.
  • Cunningham, D., Paz-Ares, L., Milan, S., Powles, R., Nicolson, M., Hickish, T., Selby, P., Treleavan, J., Viner, C. and Malpas, J., 1994. High-dose melphalan and autologous bone marrow transplantation as consolidation in previously untreated myeloma. J Clin Oncol, 12 (4), 759-763.
  • McCready, V.R. and Hickish, T.F., 1994. Somatostatin imaging function. The Lancet, 343 (8898), 617.
  • O'Brien, M.E., Matutes, E., Cunningham, D., Hill, M., Emmett, E., Ellis, P.A., Milan, S., Hickish, T., Mercieca, J. and Catovsky, D., 1994. Fludarabine in lymphoproliferative disorders: the Royal Marsden Hospital experience. Leuk Lymphoma, 14 Suppl 2, 17-23.
  • Hill, M., Cunningham, D., MacVicar, D., Roldan, A., Husband, J., McCready, R., Mansi, J., Milan, S. and Hickish, T., 1993. Role of magnetic resonance imaging in predicting relapse in residual masses after treatment of lymphoma. J Clin Oncol, 11 (11), 2273-2278.
  • Hickish, T., Cunningham, D., Colston, K., Millar, B.C., Sandle, J., Mackay, A.G., Soukop, M. and Sloane, J., 1993. The effect of 1,25-dihydroxyvitamin D3 on lymphoma cell lines and expression of vitamin D receptor in lymphoma. Br J Cancer, 68 (4), 668-672.
  • Hickish, T., Roldan, A., Cunningham, D., Mansi, J., Ashley, S., Nicolson, V., Gore, M.E., Catovsky, D. and Smith, I.E., 1993. EPIC: an effective low toxicity regimen for relapsing lymphoma. Br J Cancer, 68 (3), 599-604.
  • Scott-Mackie, P., Hickish, T., Mortimer, P., Sloane, J. and Cunningham, D., 1993. Calcipotriol and regression in T-cell lymphoma of skin. Lancet, 342 (8864), 172.
  • Powles, T.J., Hickish, T., Casey, S. and O'Brien, M., 1993. Hormone replacement after breast cancer. Lancet, 342 (8862), 60-61.
  • HICKISH, T., 1993. 2'-Chlorodeoxyadenosine : evaluation of a novel predominantly lymphocyte selective agent in lymphoid malignancies. Br J Cancer, 67, 139-143.
  • Hickish, T.F., Purvies, H., Mansi, J., Soukop, M. and Cunningham, D., 1991. Molecular monitoring of low grade non-hodgkin’s lymphoma by gene amplification. British Journal of Cancer, 64 (6), 1161-1163.
  • Hickish, T. and Cunningham, D., 1990. Gastrointestinal non-Hodgkin's lymphoma. Baillieres Clin Gastroenterol, 4 (1), 191-200.
  • Hickish, T., Colston, K.W., Bland, J.M. and Maxwell, J.D., 1989. Vitamin D deficiency and muscle strength in male alcoholics. Clin Sci (Lond), 77 (2), 171-176.
  • Hickish, T. and Cunningham, D., 1989. Detecting t(14;18) in paraffin-embedded lymphoma tissue. Lancet, 2 (8656), 218-219.
  • Hickish, T. and Cunningham, D., 1989. Detecting t(14;18) in paraffin-embedded lymphoma tissue. Lancet, 1 (8647), 1131-1132.
  • Cunningham, D., Hickish, T., Rosin, R.D., Sauven, P., Baron, J.H., Farrell, P.J. and Isaacson, P., 1989. Polymerase chain reaction for detection of dissemination in gastric lymphoma. Lancet, 1 (8640), 695-697.
  • Hickish, T., Colston, K.W., Bland, J.M. and Maxwell, J.D., 1989. Vitamin D deficiency and muscle strength in male alcoholics. Clinical Science, 77 (2), 177-182.
  • Hickish, T., Cunningham, D., Haydock, A. and Coombes, R.C., 1989. Experience with intermediate-dose (110-120 mg/m2) epirubicin. Cancer Chemother Pharmacol, 24 (1), 61-64.
  • Isles, S.R., Hickish, T. and Cunningham, D., 1988. Chemotherapy related pulmonary embolus recognized. BMJ, 297 (6652), 854.
  • Smedley, F., Hickish, T., Taube, M., Yale, C., Leach, R. and Wastell, C., 1988. Perforated duodenal ulcer and cigarette smoking. J R Soc Med, 81 (2), 92-94.
  • Smedley, F.H. and Hickish, T., 1986. Non-steroidal anti-inflammatory drugs and peptic ulcer perforation. Gut, 27 (1), 114.

Chapters

  • Cidón, E.U. and Hickish, T., 2014. Stem cells in colon cancer. Stem Cells in Cancer: Should We Believe or Not?. 127-147.

Conferences

  • Vaughan, N., Dubey, V.N., Hickish, T. and Cole, J., 2017. A Smart Device To Substitute The Neurothesiometer. In: International Design Engineering and Technical Conference 6-9 August 2017 Cleveland, Ohio, USA. ASME.
  • Earl, H.M., Hickish, T. et al., 2017. Disease-free and overall survival at 3.5 years for neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin and cyclophosphamide, for women with HER2 negative early breast cancer: ARTemis Trial. England.
  • Schneeweiss, A., Chia, S., Hickish, T., Harvey, V., Eniu, A., Waldron-Lynch, M., Eng-Wong, J., Kirk, S. and Cortes, J., 2017. Pertuzumab and trastuzumab plus standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: Efficacy analysis of a phase II cardiac safety study (TRYPHAENA).
  • Hickish, T., 2017. Modulation of platelet levels by an anti-IL-1? antibody (MABp1) in advanced colorectal cancer patients. In: ECCO2017 28 January 2017 Amsterdam.
  • Hickish, T., Andre, T., Wyrwicz, L., Saunders, M., Sarosiek, T., Nemecek, R., Kocsis, J., Stecher, M. and de Gramont, A., 2016. A pivotal phase 3 trial of MABp1 in advanced colorectal cancer. 128.
  • Hickish, T. and Purandare, L., 2015. A pilot study to assess the safety and feasibility of pre-chemotherapy assessment using telemedicine. In: Phi Mu Chapter Biannual Conference 19 June 2015 Leeds.
  • Cidon, E.U., Alonso, P., Needham, S. and Hickish, T., 2015. First cycle dose calculation in obese patients with colorectal cancers.
  • Earl, H.M., Hickish, T. et al., 2015. ARTemis: A randomised trial of bevacizumab with neo-adjuvant chemotherapy for patients with HER2-negative early breast cancer.
  • Abbey, G., Thompson, S.B.N., Hickish, T. and Heathcote, D., 2015. A meta-analysis of prevalence rates and moderating factors for cancer-related post-traumatic stress disorder. 371-381.
  • Hickish, Hickish, T. et al., 2014. ARTemis: A randomised trial of bevacizumab with neo-adjuvant chemotherapy (NACT) for patients with HER2-negative early breast cancer: primary endpoint – pathological complete response (pCR). In: NCRI Cancer Conference in the Clinical Trials Showcase 2-5 November 2014 Liverpool.
  • Petricoin, E.F., Wulfkuhle, J., Hickish, T., El-Hariry, I., Reichert, V., Vukovic, V.M., Cameron, D.A., Awada, A. and Spector, N., 2014. Gene expression and proteomic analysis to identify predictive biomarkers of response in the ENCHANT-1 Trial (NCT01677455), a Phase 2 Proof of Concept study evaluating first-line ganetespib monotherapy in women with metastatic HER2 positive or triple negat.
  • Bridgewater, J., Hickish, T. et al., 2014. Analysis of progression free survival in the New EPOC study in an all RAS wild-type population. In: ESMO 2014 Congress 26-30 September 2014 Madrid, Spain.
  • Abbey, G., Thompson, S.B.N., Hlickish, T. and Heathcota, D., 2014. A meta-analysis of prevalence rates and moderating factors for cancer related post-traumatic stress disorder.
  • Cameron, D.A., Hickish, T. et al., 2014. Targeting HSP90 in breast cancer: Enchant-1 (NCT01677455) phase 2 proof of concept study of ganetespib in first-line treatment of women with metastatic breast cancer.
  • Moyers-Ruiz, L., Thompson, S.B.N., Hickish, T. and Mayers, A., 2014. Prospective memory and cognitive impairment in breast cancer patients. In: 4th International Conference on Prospective Memory 26-30 May 2014 Suor Orsola Benincasa University, Naples.
  • Cameron, D., Spector, N., Gomez, H., Hickish, T., Vandat, L., Kim, S.B., Sheldon, E., El-Hariry, I., Perez, E. and Awada, A., 2014. Targeting HSP90 in breast cancer: ENCHANT-1 (NCT01677455) phase 2 proof of concept study of ganetespib in first-line treatment of women with metastatic HER2 positive or triple negative breast cancer (TNBC). S98.
  • André, T., Hickish, T. et al., 2014. MOSAIC study: Actualization of Overall Survival (OS) with 10 years follow up and evaluation of BRAF by GERCOR and MOSAIC investigators. In: ESMO 2014 26-30 September 2014 Madrid, Spain.
  • Una Cidon, E., Hickish, T. and Alonso, P., 2014. Cetuximab as Monotherapy in Elderly Patients with Metastatic Colorectal Cancer. In: ESMO World GI 2014 25-28 June 2014 Barcelona, Spain.
  • Una Cidon, E., Hickish, T. and Alonso, P., 2014. Cardiac Toxicity with Fluoropyrimidines in Colorectal Cancer. In: ESMO World GI 2014 25-28 June 2014 Barcelona, Spain.
  • Earl, H., Hickish, T. et al., 2014. ARTemis: A randomised trial of bevacizumab with neo-adjuvant chemotherapy (NACT) for patients with HER2-negative early breast cancer: primary endpoint – pathological complete response (pCR). In: NCRI Cancer Conference in the Clinical Trials Showcase 2-5 November 2014 Liverpool.
  • Schroeder, J.W., Dubey, V., Hickish, T. and Cole, T., 2014. Intelligent Agent Based Software Architecture of a Wearable Electrotactile Feedback System for Balance Improvement. In: International Academic Conference on Engineering, Internet and Technology 12-13 December 2014 Prague.
  • Moyers-Ruiz, L., Thompson, S.B.N., Hickish, T. and Mayers, A., 2013. Cognitive decline as a result of impaired sleep and glucose levels during chemotherapy treatment in breast cancer patients. In: American Society of Clinical Oncology 31 May-4 June 2013 McCormick Place, Chicago, USA.
  • Flejou, J.-F., Hickish, T. et al., 2013. Effect of adding oxaliplatin to adjuvant 5-fluorouracil/leucovorin (5FU/LV) in patients with defective mismatch repair (dMMR) colon cancer stage II and III included in the MOSIAC study.
  • Primrose, J.N., Hickish, T. et al., 2013. A randomized clinical trial of chemotherapy compared to chemotherapy in combination with cetuximab in k-RAS wild-type patients with operable metastases from colorectal cancer: The new EPOC study.
  • Hickish, T., Mehta, A., Jain, M., Huang, C.-S., Kovalenko, N., Udovitsa, D., Pemberton, K., Uttenreuther-Fischer, M., Tseng, L.-M. and Grp, L.-B.2.S., 2012. LUX-Breast 2: Phase II, open-label study of oral afatinib in HER2-overexpressing metastatic breast cancer (MBC) patients (pts) who progressed on prior trastuzumab and/or lapatinib.
  • Schroeder, J.W., Dubey, V.N., Hickish, T., Cole, J., Mecheraoui, C. and Swain, I., 2012. Applications of electrical stimulation and electrotactile feedback in human spaceflight. In: 63rd International Astronautical Congress 1-5 October 2012 Naples, Italy.
  • Moyers-Ruiz, L., Hickish, T. and Thompson, S., 2012. Prospective and working memory decline as a result of impaired sleep and/or impared blood glucose in breast cancer patients during chemotherapy treatment.
  • Hickish, T., Tseng, L.-M., Mehta, A.O., Tsang, J., Kovalenko, N., Udovitsa, D., Pelling, K., Uttenreuther-Fischer, M.M., Huang, C.-S. and Grp, L.-B.S., 2012. LUX-breast 2: Phase II, open-label study of oral afatinib in HER2-overexpressing metastatic breast cancer (MBC) patients (pts) who progressed on prior trastuzumab (T) and/or lapatanib (L).
  • Schroeder, J.W., Dubey, V.N., Hickish, T.F. and Cole, J., 2012. Case Study on Repeatability of a Threshold-Based Calibration Method for Electrocutaneous Feedback Systems. In: Design of Medical Devices 10-12 April 2012 Minneapolis, Minnesota, USA.
  • Schroeder, J.W., Dubey, V.N., Hickish, T.F. and Cole, J., 2012. Wearable Electrocutaneous Feed-back System: A Smart Device to Compensate for Sensation Loss. In: Design of Medical Devices 10-12 April 2012 Minneapolis, Minnesota, USA.
  • Moyers-Ruiz, L., Thompson, S.B.N. and Hickish, T., 2012. Prospective and working memory decline in breast cancer patients during chemotherapy. In: International Cognition & Cancer Task Force 15-17 March 2012 Espace Saint-Martin, Paris, France.
  • Schneeweiss, A., Chia, S., Hickish, T., Harvey, V., Hegg, R., Tausch, C., Seo, J.H., Tsai, Y.F., McNally, V. and Cortes, J., 2012. Pertuzumab and Trastuzumab in Combination with an Anthracycline-containing or an Anthracycline-free Standard Chemotherapy in the Neoadjuvant Treatment of HER2-positive Breast Cancer (TRYPHAENA). S96.
  • Moyers-Ruiz, L., Thompson, S.B.N. and Hickish, T., 2012. Longitudinal study of prospective and working memory decline in breast cancer patients undergoing chemotherapy. In: British Psychosocial Oncology Society Annual Conference 19-20 January 2012 Metropole Hotel, Leeds.
  • Schroeder, J., Dubey, V., Hickish, T. and Cole, J., 2012. Multisensory Intelligent Feedback System for Sensory Substitution using Electrical Stimulation. In: DEC Researchers Poster Conference 2012 Bournemouth.
  • Schroeder, J., Dubey, V., Hickish, T. and Cole, J., 2012. Creation of Artificial Sensation by Tactile Sensing and Intelligent Stimulation of Sensory Nerves. In: DEC Researchers Poster Conference. December 2012 Bournemouth.
  • Schneeweiss, A., Hickish, T. et al., 2011. Neoadjuvant Pertuzumab and Trastuzumab Concurrent or Sequential with an Anthracycline-Containing or Concurrent with an Anthracycline-Free Standard Regimen: A Randomized Phase II Study (TRYPHAENA).
  • Shipway, R., Jones, I. and Holloway, I., 2011. Healthy Options? Putting your (Running) body on the line. International Sociology of Sport Association.
  • Schroeder, J.W., Dubey, V.N., Hickish, T.F. and Cole, J., 2011. Electrocutaneous feedback system to improve the estimation of pressure applied to the foot. In: International Conference on Biomedical Electronics and Devices (BIODEVICES 2011) 26-29 January 2011 Rome, Italy.
  • Schroeder, J.W., Dubey, V.N., Hickish, T. and Cole, J., 2011. Electrocutaneous Feedback System to Improve the Estimation of Pressure Applied to the Foot. SciTePress, 386-390.
  • Schroeder, J., Dubey, V., Hickish, T. and Cole, J., 2011. Electrocutaneous Feedback System for Patients with Loss of Sensation in their Feet. In: Salisbury FES User Day 2011 Salisbury.
  • Hickish, T., Wheatley, D., Lin, N., Carey, L., Houston, S., Mendelson, D., Solca, F., Uttenreuther-Fischer, M., Jones, H. and Winer, E., 2009. Use of BIBW 2992, a Novel Irreversible EGFR/HER1 and HER2 Tyrosine Kinase Inhibitor To Treat Patients with HER2-Positive Metastatic Breast Cancer after Failure of Treatment with Trastuzumab. 785S.
  • Purandare, L., Hickish, T., Astras, G., Penfold, S., Thomas, F. and Kerr, D., 2009. Impaired glucose tolerance in non-diabetic women during adjuvant chemotherapy for breast cancer. 309.
  • Purandare, L., Baker, R. and Hickish, T., 2009. Can oncology nurses and other allied health professionals learn to treat post traumatic stress disorder in cancer survivors. 196.
  • Wong, R., Saffery, C., Barbachano, Y., Chau, I., Valle, J., Hickish, T., Mudan, S., Khan, A., Chua, Y.J. and Cunningham, D., 2009. BOXER: A multicentre phase II trial of capecitabine and oxaliplatin plus bevacizumab as neoadjuvant treatment for patients with liver-only metastases from colorectal cancer unsuitable for upfront resection. 344-345.
  • Hickish, T., Wheatley, D., Lin, N., Carey, L., Houston, S., Mendelson, D., Solca, F., Uttenreuther-Fischer, M., Jones, H. and Winer, E., 2009. Use of BIBW 2992, a novel irreversible EGFR/HER2 tyrosine kinase inhibitor (TKI), to treat patients with HER2-positive metastatic breast cancer after failure of treatment with trastuzumab.
  • Earl, H.M., Hickish, T. et al., 2009. Neo-tAnGo: A neoadjuvant randomized phase III trial of epirubicin/cyclophosphamide and paclitaxel +/- gemcitabine in the treatment of women with high-risk early breast cancer (EBC): First report of the primary endpoint, pathological complete response (pCR).
  • de Gramont, A., Boni, C., Navarro, M., Tabernero, J., Hickish, T., Topham, C., Bonetti, A., Clingan, P., Lorenzato, C. and Andre, T., 2007. FOLFOX4 in adjuvant treatment of colon cancer: Survival results from the mosaic trial. VII23.
  • Cassidy, J., Bjarnason, G.A., Hickish, T., Topham, C., Provencio, M., Bodoky, G., Landherr, L., Koralewski, P., Lopez-Vivanco, G. and Said, G., 2006. Randomized double blind (DB) placebo (Plcb) controlled phase III study assessing the efficacy of xaliproden (X) in reducing the cumulative peripheral sensory neuropathy (PSN) induced by the oxaliplatin (Ox) and 5-FU/LV combination (FOLFOX4) in first-line treatment of patients (pts) with metastatic colorectal cancer (MCRC). 147S.
  • de Gramont, A., Hickish, T. et al., 2005. Oxaliplatin/5FU/LV in the adjuvant treatment of stage II and stage III colon cancer: Efficacy results with a median follow-up of 4 years. 246S.
  • Trumper, M.J., Norman, A.R., Ross, P.J., Cunningham, D., Hawkins, R., Seymour, M., Harper, P., Iveson, T., Nicholson, M. and Hickish, T., 2004. Patients aged 70 or older (>= 70) with advanced oesophagogastric cancer (OGC) experience similar benefits from palliative chemotherapy compared to younger patients. 318S.
  • Norman, A.R., Chau, I., Iveson, T., Hill, M., Hickish, T., Lofts, F., Jodrell, D., Shellito, P., Oates, J. and Cunningham, D., 2004. Longitudinal quality of life (QoL) and quality adjusted survival (QAS) in a randomised controlled trial (RCT) comparing bolus (24 weeks) vs. protracted venous infusion (PVI 12 weeks) 5-FU as adjuvant chemotherapy for colorectal cancer (CRC). 276S.
  • Hickish, T., Boni, C., Navarro, M., Tabernero, J., Topham, C., Bonetti, A., Clingan, P., Figer, A., Andre, T. and De Gramont, A., 2004. FOLFOX4 as adjuvant treatment for stage II colon cancer (CC): Subpopulation data from the MOSAIC trial. 274S.
  • Starling, N., Chau, I., Norman, A.R., Tait, D., Iveson, T., Hill, M., Hickish, T., Lofts, F., Jodrell, D. and Cunningham, D., 2004. A randomised comparison between six months of bolus fluorouracil (5-FUV leucovorin (LV) and twelve weeks of protracted venous infusion (PVI) 5-FU as adjuvant treatment in colorectal cancer: An update with 5 years' follow-up. 250S.

Patents

Memberships

  • American Society of Clinical Oncology, Member,
  • Association of Cancer Physicians, Member,
  • Royal College of Physicians, Fellow,
The data on this page was last updated at 04:01 on August 20, 2017.